422.5 USD
+16.1 (+3.96%)
422.5 USD
0 (0%)
Taking everything into account, ALNY scores 6 out of 10 in our fundamental rating. ALNY was compared to 530 industry peers in the Biotechnology industry. Both the profitability and the financial health of ALNY get a neutral evaluation. Nothing too spectacular is happening here. ALNY is not overvalued while it is showing excellent growth. This is an interesting combination. This makes ALNY very considerable for growth investing!
1. Profitability
1.1 Basic Checks
ALNY had positive earnings in the past year.
In the past year ALNY had a positive cash flow from operations.
ALNY had negative earnings in each of the past 5 years.
In the past 5 years ALNY reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.90%, ALNY belongs to the top of the industry, outperforming 88.68% of the companies in the same industry.
The Return On Equity of ALNY (18.63%) is better than 95.47% of its industry peers.
ALNY has a Return On Invested Capital of 6.34%. This is amongst the best in the industry. ALNY outperforms 92.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.9% | ||
| ROE | 18.63% | ||
| ROIC | 6.34% |
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALNY has a Profit Margin of 1.36%. This is amongst the best in the industry. ALNY outperforms 88.87% of its industry peers.
The Operating Margin of ALNY (8.25%) is better than 90.57% of its industry peers.
ALNY has a Gross Margin of 83.90%. This is amongst the best in the industry. ALNY outperforms 86.60% of its industry peers.
In the last couple of years the Gross Margin of ALNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.25% | ||
| PM (TTM) | 1.36% | ||
| GM | 83.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
ALNY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ALNY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALNY has been increased compared to 5 years ago.
Compared to 1 year ago, ALNY has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 6.34 indicates that ALNY is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 6.34, ALNY is doing good in the industry, outperforming 75.85% of the companies in the same industry.
ALNY has a debt to FCF ratio of 11.32. This is a negative value and a sign of low solvency as ALNY would need 11.32 years to pay back of all of its debts.
ALNY has a Debt to FCF ratio of 11.32. This is amongst the best in the industry. ALNY outperforms 90.57% of its industry peers.
ALNY has a Debt/Equity ratio of 10.22. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 10.22, ALNY is not doing good in the industry: 80.75% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.22 | ||
| Debt/FCF | 11.32 | ||
| Altman-Z | 6.34 |
ROIC/WACC0.74
WACC8.54%
2.3 Liquidity
ALNY has a Current Ratio of 2.54. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
ALNY's Current ratio of 2.54 is on the low side compared to the rest of the industry. ALNY is outperformed by 70.00% of its industry peers.
ALNY has a Quick Ratio of 2.49. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
ALNY has a worse Quick ratio (2.49) than 68.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.54 | ||
| Quick Ratio | 2.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 119.47% over the past year.
The Revenue has grown by 53.24% in the past year. This is a very strong growth!
The Revenue has been growing by 59.21% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)119.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%342.53%
Revenue 1Y (TTM)53.24%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%149.35%
3.2 Future
Based on estimates for the next years, ALNY will show a very strong growth in Earnings Per Share. The EPS will grow by 69.83% on average per year.
Based on estimates for the next years, ALNY will show a very strong growth in Revenue. The Revenue will grow by 33.34% on average per year.
EPS Next Y186.28%
EPS Next 2Y128.19%
EPS Next 3Y100.69%
EPS Next 5Y69.83%
Revenue Next Year67.6%
Revenue Next 2Y54.86%
Revenue Next 3Y45.29%
Revenue Next 5Y33.34%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 828.43 indicates a quite expensive valuation of ALNY.
Based on the Price/Earnings ratio, ALNY is valued cheaply inside the industry as 88.68% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ALNY to the average of the S&P500 Index (26.92), we can say ALNY is valued expensively.
The Price/Forward Earnings ratio is 60.71, which means the current valuation is very expensive for ALNY.
Based on the Price/Forward Earnings ratio, ALNY is valued cheaper than 90.00% of the companies in the same industry.
ALNY is valuated expensively when we compare the Price/Forward Earnings ratio to 23.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 828.43 | ||
| Fwd PE | 60.71 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALNY is valued cheaper than 89.25% of the companies in the same industry.
90.75% of the companies in the same industry are more expensive than ALNY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 252.15 | ||
| EV/EBITDA | 162.72 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of ALNY may justify a higher PE ratio.
ALNY's earnings are expected to grow with 100.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.45
PEG (5Y)N/A
EPS Next 2Y128.19%
EPS Next 3Y100.69%
5. Dividend
5.1 Amount
No dividends for ALNY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
422.5
+16.1 (+3.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.97%
Inst Owner Change0%
Ins Owners0.2%
Ins Owner Change6.38%
Market Cap55.82B
Revenue(TTM)3.21B
Net Income(TTM)43.56M
Analysts78.92
Price Target496.41 (17.49%)
Short Float %3.22%
Short Ratio3.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)103.88%
Min EPS beat(2)30.6%
Max EPS beat(2)177.15%
EPS beat(4)3
Avg EPS beat(4)65.69%
Min EPS beat(4)-2.21%
Max EPS beat(4)177.15%
EPS beat(8)7
Avg EPS beat(8)53.79%
EPS beat(12)10
Avg EPS beat(12)49.23%
EPS beat(16)10
Avg EPS beat(16)28.59%
Revenue beat(2)2
Avg Revenue beat(2)20.36%
Min Revenue beat(2)15.49%
Max Revenue beat(2)25.23%
Revenue beat(4)2
Avg Revenue beat(4)9.94%
Min Revenue beat(4)-0.56%
Max Revenue beat(4)25.23%
Revenue beat(8)4
Avg Revenue beat(8)11.04%
Revenue beat(12)7
Avg Revenue beat(12)14.54%
Revenue beat(16)8
Avg Revenue beat(16)8.99%
PT rev (1m)0.87%
PT rev (3m)8.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.01%
EPS NY rev (1m)0%
EPS NY rev (3m)60.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.47%
Revenue NY rev (1m)0.26%
Revenue NY rev (3m)6.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 828.43 | ||
| Fwd PE | 60.71 | ||
| P/S | 17.39 | ||
| P/FCF | 252.15 | ||
| P/OCF | 209.94 | ||
| P/B | 238.64 | ||
| P/tB | 238.64 | ||
| EV/EBITDA | 162.72 |
EPS(TTM)0.51
EY0.12%
EPS(NY)6.96
Fwd EY1.65%
FCF(TTM)1.68
FCFY0.4%
OCF(TTM)2.01
OCFY0.48%
SpS24.3
BVpS1.77
TBVpS1.77
PEG (NY)4.45
PEG (5Y)N/A
Graham Number4.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.9% | ||
| ROE | 18.63% | ||
| ROCE | 8.03% | ||
| ROIC | 6.34% | ||
| ROICexc | 36.59% | ||
| ROICexgc | 36.59% | ||
| OM | 8.25% | ||
| PM (TTM) | 1.36% | ||
| GM | 83.9% | ||
| FCFM | 6.9% |
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.22 | ||
| Debt/FCF | 11.32 | ||
| Debt/EBITDA | 7.44 | ||
| Cap/Depr | 79.01% | ||
| Cap/Sales | 1.39% | ||
| Interest Coverage | 2.25 | ||
| Cash Conversion | 82.82% | ||
| Profit Quality | 508.12% | ||
| Current Ratio | 2.54 | ||
| Quick Ratio | 2.49 | ||
| Altman-Z | 6.34 |
F-Score5
WACC8.54%
ROIC/WACC0.74
Cap/Depr(3y)112.53%
Cap/Depr(5y)140.08%
Cap/Sales(3y)3.96%
Cap/Sales(5y)7.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)119.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%342.53%
EPS Next Y186.28%
EPS Next 2Y128.19%
EPS Next 3Y100.69%
EPS Next 5Y69.83%
Revenue 1Y (TTM)53.24%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%149.35%
Revenue Next Year67.6%
Revenue Next 2Y54.86%
Revenue Next 3Y45.29%
Revenue Next 5Y33.34%
EBIT growth 1Y240.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year548.09%
EBIT Next 3Y166.8%
EBIT Next 5Y135.27%
FCF growth 1Y432.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13193.2%
OCF growth 3YN/A
OCF growth 5YN/A
ALNYLAM PHARMACEUTICALS INC / ALNY FAQ
Can you provide the ChartMill fundamental rating for ALNYLAM PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 6 / 10 to ALNY.
What is the valuation status for ALNY stock?
ChartMill assigns a valuation rating of 5 / 10 to ALNYLAM PHARMACEUTICALS INC (ALNY). This can be considered as Fairly Valued.
How profitable is ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
ALNYLAM PHARMACEUTICALS INC (ALNY) has a profitability rating of 6 / 10.
How financially healthy is ALNYLAM PHARMACEUTICALS INC?
The financial health rating of ALNYLAM PHARMACEUTICALS INC (ALNY) is 5 / 10.
What is the earnings growth outlook for ALNYLAM PHARMACEUTICALS INC?
The Earnings per Share (EPS) of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 186.28% in the next year.